The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market in a decade.

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Zepbound and Wegovy are prescription drugs used for weight loss and weight management. Compare their uses, cost, effectiveness, side effects, and more.

The stock could soar later this year, provided the oral version aces phase 2 studies. Viking Therapeutics is somewhat risky, but it also has significant upside potential. 10 stocks we like better than ...

The Indianapolis-based pharmaceutical giant released its second-quarter earnings Thursday along with data from the latest ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

Eli Lilly ( LLY -0.24%) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding financial results, the company has become the largest healthcare player ...

The FDA gave Zepbound “fast track” approval to study its uses for overweight or obese adults with comorbidities like sleep apnea in 2022, around when weight-loss drugs began growing in popularity.

This section describes Zepbound’s typical dosage, but always follow the dosage your doctor prescribes. Form and strengths Zepbound comes as a liquid solution in prefilled, disposable injection ...